Abstract Background and Objectives Atrial fibrillation (AF) and the associated risk of stroke
are emerging epidemics throughout the world. Suboptimal use of oral anticoagulants for …

Background Patients with a mechanical prosthetic heart valve implantation need to be
treated with a vitamin K antagonist (VKA) due to a substantially high risk of …

Atrial fibrillation (AF) is associated with significant risk of stroke and other thromboembolic
events, which can be effectively prevented using oral anticoagulation (OAC) with either …

Aims Randomized trials showed non-inferior or superior results of the non-vitamin-K-
antagonist oral anticoagulants (NOACs) compared with warfarin. The aim of this study was …

Background Non-vitamin K dependent oral anticoagulants (NOACs) significantly decrease
overall major bleeding rates compared with vitamin K antagonists (VKAs) but there is …

Abstract Context: Direct oral anticoagulants (DOACs) may be as effective as, and at times
safer than, warfarin. Because DOACs do not require regular serum level monitoring …

Background New oral anticoagulants (NOAC) and the Watchman device represent an
alternative to warfarin for stroke prophylaxis in atrial fibrillation (AF) patients. However, no …

Abstract Purpose Direct oral anticoagulants (DOACs) have a better safety and efficacy
profile than warfarin and are currently recommended for stroke prevention in non-valvular …

El tratamiento farmacológico de la fibrilación auricular recae en dos aspectos
fundamentales, la prevención del ictus mediante la anticoagulación oral y el control de la …

Dabigatran and rivaroxaban are novel nonvitamin K antagonist oral anticoagulants (NOACs)
approved for thromboprophylaxis in atrial fibrillation (AF). In Turkey, like other countries, the …